Best Genomics Companies in Cambridge, United States

Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.

Developer of gene delivery systems for cell therapy. The proprietary non-viral flowfect technology combines electric fields and continuous fluid flow to engineer cells by delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. The platform has applications in the discovery and manufacturing of cell and gene therapies.

Funding rounds

• Apr 2026Series B—
• Apr 2025Grant (prize money)$1.4M
• Feb 2025Grant (prize money)$1.4M
• Aug 2024Grant (prize money)$1.6M

Founders & team

Cullen BuieCo-FounderPaulo GarciaCo-FounderMichael ChiuChief Executive Officer

Investors

MassVentures, Horizons Ventures, Engine Ventures, NIAID, America’s Seed Fund, Alexandria

Provider of genomic technologies and drug discovery platform. This platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening for enabling the discovery of proteins. The company has also identified a new CRISPR enzyme using its discovery platform.

Funding rounds

• Oct 2025Series C—
• Mar 2025Series C$73.5M
• Nov 2021Series B$215M
• Aug 2017Series A$15.6M

Founders & team

David ScottCo-FounderWinston Yan MdCo-Founder

Investors

Temasek, TCG Crossover, Arch Venture Partners, Ally Bridge Group, ArrowMark Partners, GreatPoint Ventures

Tech stack

WordpressMysqlPhpWordpress Super CacheContact Form 7Yoast Seo

Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.

Funding rounds

• Oct 2025Post IPO$15M
• Aug 2023Post IPO$80M
• Aug 2020Series B$50M
• Apr 2020Series B$60M

Founders & team

Barbara Weber MdPresident and CEO

Investors

Casdin Capital, Boxer Capital, Third Rock Ventures, Gilead, Tavistock Group, Roche

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

Provider of a drug prediction and development tool for researchers. The platform helps to code the discrete set of combinatorial rules used by any human cell type central to disease pathology. It uses machine learning algorithms to solve for druggable targets to control the output of any disease gene of interest.

Funding rounds

• Sep 2025Post IPO$100M
• Jun 2022Series B$100.5M
• Mar 2021Series B$45M
• Apr 2018Series A$34.1M

Founders & team

Josh Mandel-BrehmCEO

Investors

Enavate Sciences, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, Gaingels

Tech stack

Apple Icloud MailCookieyesCore-JsDocusignFlywheelGodaddy

QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.2/7.3 channel & CSF cartridge device to remove DPR proteins.

Funding rounds

• Aug 2025Series B$20M
• Mar 2023Series B$88M
• Sep 2022Grant (prize money)$300K
• Jul 2020Grant (prize money)$107.4K

Founders & team

Kasper RoetFounder & CEO

Investors

Polaris Partners, Mission BioCapital, MP Healthcare Venture Management, Dolby Family Ventures, SV Health Investors, Droia Ventures

Tech stack

AccessibeApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesGenesis Blocks

Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.

Funding rounds

• May 2025Series B$153M
• Nov 2022Series A$45M
• Jun 2021Series A$52.1M
• May 2021Grant (prize money)$399.5K

Founders & team

Tasuku KitadaCo-founder

Investors

Playground Global, Alexandria, ANRI, Redmile Group, BeiGene, Camford Capital

Innovating microbial solutions for human health, focusing on aging well. The company rapidly innovates and delivers breakthrough solutions for unmet medical needs, particularly in aging health. They are committed to advancing health outcomes through microbial science. Their core values include integrity, scientific rigor, diversity and inclusion, tenacity, a sense of purpose, transparency, and innovation. They develop products to address dietary needs related to rheumatoid arthritis, psoriatic arthritis, and cellular aging. The company uses a rigorous process involving discovery, development, preclinical testing, and clinical trials. They aim to provide trustworthy solutions for health conditions, incorporating the highest level of scientific rigor into every aspect of their process. They are dedicated to improving collective health outcomes and providing transparent formulations.

Funding rounds

• Nov 2025Series B$9.9M
• Aug 2024Series B$1M
• May 2023Series B$15M
• Sep 2020Series A$11.3M

Founders & team

Gerardo ToledoCo-Founder & CEO

Investors

Illumina, Bold Capital Partners, Viking Global Investors, GISEV, S2G Investments, GG1978

Tech stack

WordpressMysqlPhpWp RocketContact Form 7Yoast Seo

Developer of RNA-based therapeutics for multiple disorders. It is building compound libraries likely to recognize the RNA target sites and modulate their function, particularly those mediated by the regulatory proteins. The data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation.

Funding rounds

• 2025Series A—
• Nov 2022Series A$52M
• May 2021Seed$18M
• Sep 2020Grant (prize money)$400K

Founders & team

Zhiping WengCo-FounderSimon XiCo-Founder and CEOTravis WagerCo-Founder

Investors

Boehringer Ingelheim Venture Fund, Matrix Partners China, AstraZeneca, Delos Capital, Matrix, Lilly Asia Ventures

Developer of a gene transplantation platform for humanizing pig cells. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. These organs will be harvested in the donor pig and safely transplanted to human patients. The company's technology is based on the next-generation genome engineering toolset and CRISPR.

Funding rounds

• Sep 2024Series D$191M
• Feb 2024Series C$25.4M
• Mar 2021Series C$125M
• Nov 2019Series B$100M

Founders & team

Luhan YangCo-FounderMichael CurtisPresident and CEO

Investors

Biomatics Capital, Arch Venture Partners, Khosla Ventures, Alta Partners, Heritage Provider Network, Alexandria

Tech stack

Apple Icloud MailBunnyCloudflareCookieyesCraft CmsGatsby

Developer of gene therapies for rare and common diseases. It offers RNA editing therapeutics based on a platform RESTORE+ to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Funding rounds

• Apr 2025Series B$155M
• Jul 2024Series A$60M
• Sep 2023Series A$30M

Founders & team

Jin LiCo-FounderThorsten StafforstCo-Founder

Investors

Arch Venture Partners, ND Capital, Novalis LifeSciences, Codon Capital, Fast Track Initiative, Forbion

Tech stack

AccessibeApple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCookieyes

Developer of therapeutics to modulate neurodegenerative stress granules. The company focuses on RNA binding proteins, and the first pipeline is based on TDP-43, which is genetically linked to amyotrophic lateral sclerosis, and a major pathology in amyotrophic lateral sclerosis, frontotemporal dementia, and Alzheimer's disease.